(Q84479896)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21719098%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Anti-CD3 antibodies for type 1 diabetes: beyond expectations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21719098%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

Jean-François Bach

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21719098%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

28 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21719098%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21719098%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

378

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21719098%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

9790

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21719098%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

459-460

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21719098%20AND%20SRC:MED&resulttype=core&format=json

Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

Effects of insulin in relatives of patients with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

GAD treatment and insulin secretion in recent-onset type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

CD3-specific antibodies: a portal to the treatment of autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960980-X

7 January 2021

10.1016/S0140-6736(11)60980-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21719098%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference